Project Grant HT94252410578
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$538K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
This federal Project Grant award, valued at $431,750.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research on the role of H19X noncoding RNAs in the pathogenesis of myotonic dystrophy type I. The award was granted to the University of Houston System, a Hispanic Serving Institution and comprehensive research university, to conduct this scientific investigation over a 2-year period from December 1, 2024 to November...
This federal Project Grant award of $777,659.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Children's Research Institute in Washington, D.C. on the use of pro-resolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy. The award period runs from August 1, 2025 to July 31, 2028. The funded research aims to develop innovative therapeutic approaches and medical...
This $661,501 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the period of September 1, 2024 through August 31, 2027. The award will fund research to develop AAV (adeno-associated virus) vectors targeted to muscle and muscle stem cells, which offer improved therapeutic efficacy and safety for treating Duchenne muscular dystrophy. UCLA, through...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
This $953,125 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in nonambulatory individuals with Duchenne muscular dystrophy. The research project will run from November 1, 2024 to October 31, 2027 and aims to advance understanding of neurodegenerative diseases...
The University of Texas Health Science Center at Houston was awarded a $1,498,514 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program. The grant will fund research from September 2022 through September 2026 to improve functional performance in transfemoral amputees through somatosensory augmentation. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...